Los Angeles Capital Management
TARA icon

Los Angeles Capital Management’s Protara Therapeutics TARA Stock Holding History

Los Angeles Capital Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,545
Closed -$67.6K – 2545
2025
Q3 		$67.6K Hold
15,545
– – ﹤0.01% 1331
2025
Q2 		$47.1K Buy
+15,545
New +$53.6K ﹤0.01% 1310

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Los Angeles Capital Management's TARA Position: Q4 2025 in Review

Los Angeles Capital Management sold out of Protara Therapeutics (TARA) in Q4 2025, closing a stake of 15,545 shares — an estimated $67.6K sold.

Los Angeles Capital Management first reported a position in TARA in Q2 2025 and held it in 2 quarters. The position peaked at $67.6K in Q3 2025. 105 funds tracked by Wall St. Rank hold TARA as of Q4 2025.

  • Los Angeles Capital Management reported no remaining Protara Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Los Angeles Capital Management sold 15,545 Protara Therapeutics shares in Q4 2025, an estimated $67.6K.
  • Los Angeles Capital Management first reported a position in Protara Therapeutics in Q2 2025 and held it in 2 quarters.
  • Los Angeles Capital Management's Protara Therapeutics position peaked at $67.6K in Q3 2025.
  • 105 funds tracked by Wall St. Rank held Protara Therapeutics as of Q4 2025.

Based on Los Angeles Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.